Product Description
Mechanisms of Action: FcRn Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: argenx
Company Location: Europe
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - argenx announced they will present P1 Inflammation results in 1H26 for ARGX-213
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06968338 |
ARGX-213-2401 | P1 |
Completed |
Healthy Volunteers |
2026-03-20 |
2026-04-24 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
argenx Highlights 2026 Strategic Priorities |
|
10/30/2025 |
News Article |
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update |
|
05/08/2025 |
News Article |
argenx Reports First Quarter 2025 Financial Results and Provides Business Update |
|
02/27/2025 |
News Article |
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update |